Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system.

[1]  M. Fornage,et al.  Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking. , 2007, Atherosclerosis.

[2]  I. Fleming,et al.  From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: Epoxyeicosatrienoic acids (EETs) and cell signaling. , 2006, Pharmacology & therapeutics.

[3]  J. Liao,et al.  Cytochrome P450 epoxygenase CYP2J2 and the risk of coronary artery disease. , 2006, Trends in cardiovascular medicine.

[4]  E. Jacobs,et al.  Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vasculature. , 2006, American journal of physiology. Heart and circulatory physiology.

[5]  J. Imig,et al.  PPAR-α Activator Fenofibrate Increases Renal CYP-Derived Eicosanoid Synthesis and Improves Endothelial Dilator Function in Obese Zucker Rats , 2006 .

[6]  D. Gutterman,et al.  Emerging role of epoxyeicosatrienoic acids in coronary vascular function , 2006, European journal of clinical investigation.

[7]  R. Busse,et al.  Cytochrome P450 Epoxygenase Gene Function in Hypoxic Pulmonary Vasoconstriction and Pulmonary Vascular Remodeling , 2006, Hypertension.

[8]  R. Busse,et al.  Endothelium-derived epoxyeicosatrienoic acids and vascular function. , 2006, Hypertension.

[9]  H. Miura,et al.  Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. , 2006, American journal of physiology. Heart and circulatory physiology.

[10]  R. Weiss,et al.  Attenuation of Vascular Smooth Muscle Cell Proliferation by 1-Cyclohexyl-3-dodecyl Urea Is Independent of Soluble Epoxide Hydrolase Inhibition , 2006, Journal of Pharmacology and Experimental Therapeutics.

[11]  Baolin Zhang,et al.  Fibroblast Growth Factor-2 Is a Downstream Mediator of Phosphatidylinositol 3-Kinase-Akt Signaling in 14,15-Epoxyeicosatrienoic Acid-induced Angiogenesis* , 2006, Journal of Biological Chemistry.

[12]  M. Fornage,et al.  Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. , 2006, Human molecular genetics.

[13]  J. Falck,et al.  14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-alpha. , 2006, American journal of physiology. Heart and circulatory physiology.

[14]  R. Busse,et al.  Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis , 2005, Journal of Cell Science.

[15]  J. Shyy,et al.  The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Hui,et al.  Arachidonic Acid Epoxygenase Metabolites Stimulate Endothelial Cell Growth and Angiogenesis via Mitogen-Activated Protein Kinase and Phosphatidylinositol 3-Kinase/Akt Signaling Pathways , 2005, Journal of Pharmacology and Experimental Therapeutics.

[17]  A. Pozzi,et al.  Characterization of 5,6- and 8,9-Epoxyeicosatrienoic Acids (5,6- and 8,9-EET) as Potent in Vivo Angiogenic Lipids* , 2005, Journal of Biological Chemistry.

[18]  J. Shyy,et al.  Activation of Peroxisome Proliferator-Activated Receptor α by Substituted Urea-Derived Soluble Epoxide Hydrolase Inhibitors , 2005, Journal of Pharmacology and Experimental Therapeutics.

[19]  D. Zeldin,et al.  Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. , 2005, Cancer research.

[20]  H. Kaneto,et al.  Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients. , 2005, Biochemical and biophysical research communications.

[21]  J. Falck,et al.  Stable 5,6-Epoxyeicosatrienoic Acid Analog Relaxes Coronary Arteries Through Potassium Channel Activation , 2005, Hypertension.

[22]  Kevin R. Smith,et al.  Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Liao,et al.  Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. , 2005, Archives of biochemistry and biophysics.

[24]  R. Busse,et al.  Cytochrome P4502C9-Derived Epoxyeicosatrienoic Acids Induce the Expression of Cyclooxygenase-2 in Endothelial Cells , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[25]  J. Pollock,et al.  Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[26]  B. Hammock,et al.  Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. , 2004, American journal of physiology. Heart and circulatory physiology.

[27]  K. Lindpaintner,et al.  Risk of Coronary Artery Disease Associated With Polymorphism of the Cytochrome P450 Epoxygenase CYP2J2 , 2004, Circulation.

[28]  J. Falck,et al.  Identification of 5,6-trans-Epoxyeicosatrienoic Acid in the Phospholipids of Red Blood Cells* , 2004, Journal of Biological Chemistry.

[29]  J. Pollock,et al.  Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. , 2004, Journal of the American Society of Nephrology : JASN.

[30]  W. Campbell,et al.  Membrane Potential-Dependent Inhibition of Platelet Adhesion to Endothelial Cells by Epoxyeicosatrienoic Acids , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[31]  M. Fornage,et al.  Polymorphism of the Soluble Epoxide Hydrolase Is Associated With Coronary Artery Calcification in African-American Subjects: The Coronary Artery Risk Development In Young Adults (CARDIA) Study , 2004, Circulation.

[32]  U. de Faire,et al.  Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. , 2003, Pharmacogenetics.

[33]  R. Busse,et al.  11,12-Epoxyeicosatrienoic Acid-induced Inhibition of FOXO Factors Promotes Endothelial Proliferation by Down-Regulating p27Kip1* , 2003, Journal of Biological Chemistry.

[34]  J. E. Maxwell,et al.  Polymorphisms in human soluble epoxide hydrolase. , 2003, Molecular pharmacology.

[35]  R. Sprague,et al.  Differential effects of 5,6-EET on segmental pulmonary vasoactivity in the rabbit. , 2003, American journal of physiology. Heart and circulatory physiology.

[36]  R. Busse,et al.  Cytochrome P450 2C9‐derived epoxyeicosatrienoic acids induce angiogenesis via cross‐talk with the epidermal growth factor receptor , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  S. Archer,et al.  Endothelium-Derived Hyperpolarizing Factor in Human Internal Mammary Artery Is 11,12-Epoxyeicosatrienoic Acid and Causes Relaxation by Activating Smooth Muscle BKCa Channels , 2003, Circulation.

[38]  J. Liao,et al.  Inhibition of Vascular Smooth Muscle Cell Migration by Cytochrome P450 Epoxygenase-Derived Eicosanoids , 2002, Circulation research.

[39]  R. Busse,et al.  Cytochrome P450 2C9-induced Endothelial Cell Proliferation Involves Induction of Mitogen-activated Protein (MAP) Kinase Phosphatase-1, Inhibition of the c-Jun N-terminal Kinase, and Up-regulation of Cyclin D1* , 2002, The Journal of Biological Chemistry.

[40]  H. Mohrenweiser,et al.  Cloning of CYP2J2 gene and identification of functional polymorphisms. , 2002, Molecular pharmacology.

[41]  D. Thompson,et al.  Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  B. Hammock,et al.  Soluble Epoxide Hydrolase Inhibition Lowers Arterial Blood Pressure in Angiotensin II Hypertension , 2002, Hypertension.

[43]  R. Roman,et al.  P-450 metabolites of arachidonic acid in the control of cardiovascular function. , 2002, Physiological reviews.

[44]  C. Dimitropoulou,et al.  Epoxyeicosatrienoic acid-induced relaxation is impaired in insulin resistance. , 2001, American journal of physiology. Heart and circulatory physiology.

[45]  J. Falck,et al.  Role of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factor in bovine coronary arteries. , 2001, Medical science monitor : international medical journal of experimental and clinical research.

[46]  K. Node,et al.  Activation of Gαs Mediates Induction of Tissue-type Plasminogen Activator Gene Transcription by Epoxyeicosatrienoic Acids* , 2001, The Journal of Biological Chemistry.

[47]  D. McCormack,et al.  Cytochrome P450 metabolites of arachidonic acid but not cyclooxygenase-2 metabolites contribute to the pulmonary vascular hyporeactivity in rats with acute Pseudomonas pneumonia. , 2001, The Journal of pharmacology and experimental therapeutics.

[48]  Takashi Saito,et al.  Flow-Induced Dilation of Human Coronary Arterioles: Important Role of Ca2+-Activated K+ Channels , 2001, Circulation.

[49]  M. Hoenig,et al.  Cytochrome P450 Activity and Endothelial Dysfunction in Insulin Resistance , 2000, Journal of Vascular Research.

[50]  C. Dawson,et al.  Hypoxic pulmonary vasoconstriction is modified by P-450 metabolites. , 2000, American journal of physiology. Heart and circulatory physiology.

[51]  J. Meijer,et al.  Identification and Functional Characterization of Human Soluble Epoxide Hydrolase Genetic Polymorphisms* , 2000, The Journal of Biological Chemistry.

[52]  E. Jacobs,et al.  Epoxyeicosatrienoic acids constrict isolated pressurized rabbit pulmonary arteries. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[53]  R. Busse,et al.  Cytochrome P450 2C is an EDHF synthase in coronary arteries , 1999, Nature.

[54]  K. Ley,et al.  Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. , 1999, Science.

[55]  D. Zeldin,et al.  P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. , 1999, Drug metabolism reviews.

[56]  H. Miura,et al.  Human coronary arteriolar dilation to bradykinin depends on membrane hyperpolarization: contribution of nitric oxide and Ca2+-activated K+ channels. , 1999, Circulation.

[57]  M. Hecker,et al.  Endothelium-derived hyperpolarizing factor, but not nitric oxide or prostacyclin release, is resistant to menadione-induced oxidative stress in the bovine coronary artery , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[58]  C. L. Ivey,et al.  Involvement of cytochrome P-450 enzyme activity in the control of microvascular permeability in canine lung. , 1998, American journal of physiology. Lung cellular and molecular physiology.

[59]  R. Sprague,et al.  5,6-Epoxyeicosatrienoic acid reduces increases in pulmonary vascular resistance in the dog. , 1998, American journal of physiology. Heart and circulatory physiology.

[60]  A. Takeshita,et al.  Importance of endothelium-derived hyperpolarizing factor in human arteries. , 1997, The Journal of clinical investigation.

[61]  K. Tomer,et al.  Predominant expression of an arachidonate epoxygenase in islets of Langerhans cells in human and rat pancreas. , 1997, Endocrinology.

[62]  R Busse,et al.  Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. , 1996, Circulation.

[63]  M. Fujishima,et al.  The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. , 1996, Journal of cardiovascular pharmacology.

[64]  N. Weintraub,et al.  Inhibition of cytochrome P-450 attenuates hypoxemia of acute lung injury in dogs. , 1996, The American journal of physiology.

[65]  P. Pratt,et al.  Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. , 1996, Circulation research.

[66]  K. Tomer,et al.  Molecular Cloning and Expression of CYP2J2, a Human Cytochrome P450 Arachidonic Acid Epoxygenase Highly Expressed in Heart (*) , 1996, The Journal of Biological Chemistry.

[67]  D. Koop,et al.  Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. , 1994, The Journal of pharmacology and experimental therapeutics.

[68]  V. Dzau.  Pathobiology of atherosclerosis and plaque complications. , 1994, American heart journal.

[69]  J. Falck,et al.  Enhanced synthesis of epoxyeicosatrienoic acids by cholesterol-fed rabbit aorta. , 1991, The American journal of physiology.

[70]  Y. Tamura,et al.  Possible involvement of arachidonic acid metabolites of cytochrome P450 monooxygenase pathway in vasopressin-stimulated glycogenolysis in isolated rat hepatocytes. , 1990, Archives of biochemistry and biophysics.

[71]  K. Pritchard,et al.  Atherogenic concentrations of low-density lipoprotein enhance endothelial cell generation of epoxyeicosatrienoic acid products. , 1990, The American journal of pathology.

[72]  K. Pritchard,et al.  14, 15-Epoxyeicosatrienoic acid promotes endothelial cell dependent adhesion of human monocytic tumor U937 cells. , 1990, Biochemical and biophysical research communications.

[73]  F. Fitzpatrick,et al.  Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. , 1986, The Journal of biological chemistry.

[74]  P. Comens,et al.  Arachidonic acid metabolism in isolated pancreatic islets. IV. Negative ion-mass spectrometric quantitation of monooxygenase product synthesis by liver and islets. , 1985, Biochimica et biophysica acta.

[75]  M. Mcdaniel,et al.  Arachidonic acid metabolism in isolated pancreatic islets. I. Identification and quantitation of lipoxygenase and cyclooxygenase products. , 1984, Biochimica et biophysica acta.

[76]  J. Falck,et al.  Epoxyeicosatrienoic acids stimulate glucagon and insulin release from isolated rat pancreatic islets. , 1983, Biochemical and biophysical research communications.